ARQT Arcutis Biotherapeutics

Arcutis Biotherapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

Arcutis Biotherapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

WESTLAKE VILLAGE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that , President and CEO, will present a corporate overview during the Stifel 2020 Virtual Healthcare Conference taking place November 16-18, 2020.

Details for the presentation are as follows:

        Stifel 2020 Virtual Healthcare Conference

        Presentation Date: Wednesday, November 18, 2020

        Presentation Time: 12:20 p.m. PST / 3:20 p.m. EST

The presentation will be webcast and may be accessed at the “Events & Presentations” section of the Company’s website at . Arcutis will maintain an archived replay of the webcast on its website for 30 days after the conference.

About Arcutis - Bioscience, applied to the skin.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis’ robust includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company’s lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit or follow the company on and .

Investor Contact:

Heather Rowe Armstrong

Vice President, Investor Relations & Corporate Communications



805-418-5006, Ext. 740

EN
11/11/2020

Underlying

ARQTArcutis Biotherapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Arcutis Biotherapeutics

 PRESS RELEASE
Free
ARQT Arcutis Biother...

Arcutis Management to Present at the 25th Annual Needham Virtual Healt...

Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference WESTLAKE VILLAGE, Calif., March 31, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16, 2026. Details for the Company’s participation are as follows:        Fireside Chat: Tuesday, April 14, 2026 at 11:00 am ET The webcast for this conference may be accessed via the...

March 31, 2026 1 EN
 PRESS RELEASE
Free
ARQT Arcutis Biother...

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis...

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT programZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four weeksCaregivers reported rapid improvement in itch in as little as 10 minutes in nearly half of infantsResults from additional studies acro...

March 28, 2026 1 EN
 PRESS RELEASE
Free
ARQT Arcutis Biother...

Arcutis to Present New Clinical Data in a Late-Breaking Podium Present...

Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting WESTLAKE VILLAGE, Calif., and DENVER, March 18, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new data from its clinical development program and marketed ZORYVE® (roflumilast) portfolio during the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place March 27-31 in Denver. ...

March 18, 2026 1 EN
 PRESS RELEASE
Free
ARQT Arcutis Biother...

Arcutis Announces Publication of Positive Long-Term Safety and Efficac...

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology ZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks of treatmentChildren ages 2-5 who achieved disease clearance and who switched to proactive twice-weekly application sustained disease control for a median duration of ~8 monthsThese results further support the Company’s focus on expanding options for pediatric po...

March 10, 2026 1 EN
 PRESS RELEASE
Free
ARQT Arcutis Biother...

Arcutis Announces Promotion of Mas Matsuda to Executive Vice President...

Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the promotion of Mas Matsuda, JD, currently senior vice president and general counsel, to executive vice president, chief legal officer, and corporate secretary. Mr. Matsuda will continue to lead the Company’s legal, compliance, and governance strategy in suppo...

March 5, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch